Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST
February 25 2020 - 4:30PM
Business Wire
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS;
Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused
on developing immunotherapies based on gene-edited allogeneic CAR
T-cells (UCART), announced that it will report the fourth quarter
2019 and year-end financial results on Wednesday, March 4, 2020,
after the close of the US market. The announcement will be followed
by a conference call at 7:30 AM EST / 1:30 PM CET on Thursday,
March 5, 2020, prior to the open of the US market.
The live dial-in information for the conference call is: US
& Canada only: 877-407-3104 International: 201-493-6792
In addition, a replay of the call will be available until March
19, 2020 by calling 877-660-6853 (Toll Free US & Canada);
201-612-7415 (Toll Free International), Conference ID: 13688263
About Cellectis Cellectis is developing the first of its
kind allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients. As a
clinical-stage biopharmaceutical company with over 20 years of
expertise in gene editing, Cellectis is developing life-changing
product candidates utilizing TALEN®, its gene editing technology,
and PulseAgile, its pioneering electroporation system to harness
the power of the immune system in order to target and eradicate
cancer cells.
As part of its commitment to a cure, Cellectis remains dedicated
to its goal of providing life-saving UCART product candidates to
address unmet needs for multiple cancers including acute myeloid
leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL),
multiple myeloma (MM) and non-Hodgkin lymphoma (NHL).
Cellectis headquarters are in Paris, France, with additional
locations in New York, New York and Raleigh, North Carolina.
Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and
on Euronext Growth (ticker: ALCLS). For more information, visit
www.cellectis.com.
Follow Cellectis on social media: @cellectis, LinkedIn and
YouTube.
TALEN® is a registered trademark owned by Cellectis.
Disclaimer This press release contains “forward-looking”
statements that are based on our management’s current expectations
and assumptions and on information currently available to
management. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Further information on
the risk factors that may affect company business and financial
performance is included in Cellectis’ Annual Report on Form 20-F
and the financial report (including the management report) for the
year ended December 31, 2018 and subsequent filings Cellectis makes
with the Securities Exchange Commission from time to time. Except
as required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200225006047/en/
Media: Jennifer Moore, VP of Communications,
917-580-1088, media@cellectis.com Caitlin Kasunich, KCSA Strategic
Communications, 212-896-1241, ckasunich@kcsa.com
IR: Simon Harnest, VP of Corporate Strategy and Finance,
646-385-9008, simon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Oct 2023 to Oct 2024